Thomas W M, Robertson J F, Price M R, Hardcastle J D
Department of Surgery, Queen's Medical Centre, Nottingham, UK.
Br J Cancer. 1991 Jun;63(6):975-6. doi: 10.1038/bjc.1991.213.
Serum CA19-9 levels have been measured in 34 patients with asymptomatic colorectal cancer, 39 age and sex matched subjects with healthy colons (as assessed at full colonoscopy) and 55 patients known to have liver metastases from primary colorectal cancers. In subjects with asymptomatic cancer the median CA19-9 was 12.75 U ml-1 (0.0-280.7 U ml-1), in the healthy controls the median CA19-9 was 12.80 U ml-1 (0.0-88.9 U ml-1) and in those with liver metastases was 62.5 U ml-1 (4.8-458.0 U ml-1). Levels were significantly higher in patients with metastatic disease than in patients with asymptomatic tumours or the healthy controls, however there was no significant difference between the asymptomatic group and the controls. Using an upper limit of normal of 37 U ml-1, the sensitivity of CA19-9 was 60.3% for the detection of colorectal cancer with liver metastases but only 17.6% for asymptomatic cancer. Serum CA19-9 estimation is of no value as a means of screening for asymptomatic colorectal cancer.
对34例无症状结直肠癌患者、39例年龄和性别匹配且经全结肠镜检查评估结肠健康的受试者以及55例已知有原发性结直肠癌肝转移的患者检测了血清CA19-9水平。在无症状癌症患者中，CA19-9的中位数为12.75 U/ml（0.0 - 280.7 U/ml），在健康对照组中，CA19-9的中位数为12.80 U/ml（0.0 - 88.9 U/ml），在有肝转移的患者中为62.5 U/ml（4.8 - 458.0 U/ml）。转移性疾病患者的CA19-9水平显著高于无症状肿瘤患者或健康对照组，但无症状组与对照组之间无显著差异。以37 U/ml作为正常上限，CA19-9检测结直肠癌肝转移的敏感性为60.3%，但对无症状癌症的敏感性仅为17.6%。血清CA19-9检测作为无症状结直肠癌筛查手段无价值。
